Table 1 The clinicopathological features and prognosis of 4 ALK-positive patients
Case no | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
Sex | Male | Male | Male | Male |
Age (years old) | 37 | 57 | 66 | 53 |
Primary site | Transverse colon | Left abdomen | Right middle abdomen | Ileum |
Time of diagnosis | June 20, 2018 | September 25, 2019 | December 29, 2020 | March 13, 2017 |
Histological type | Epithelioid | Epithelioid | Epithelioid and spindle | Spindle |
Maximum size of tumor (cm) | 18 | 18.5 | 15.7 | 12 |
Mitotic accounts (/5 mm2) |  > 5 |  > 10 |  > 10 |  > 10 |
Recurrence risk | High | High | High | High |
IHC | ||||
 ALK(1A4) | ( +) | ( +) | ( +) | ( +) |
 ALK(D5F3) | ( +) | ( +) | ( +) | ( +) |
PDGFRA mutation type | Exon 18 D842V | Exon18 D842 _D846delinsE | Exon 18 D842V | Exon 12 D583G |
ALK FISH | ||||
 Translocation | ( −) | ( −) | ( −) | ( −) |
 Amplification | ( −) | ( −) | ( +) | ( −) |
NGS ALK | ||||
 Fusion | ( −) | ( −) | ( −) | ( −) |
 CNI | ( −) | ( −) | ( −) | ( −) |
Recurrence time | February 2019 | NA | NA | July 16, 2018 |
Recurrence site | liver | NA | NA | Pelvic cavity |
Treatment after recurrence | Dasatinib, PD,1mth Ceritinib, PD, 1Â month | NA | NA | Surgery |
OS (month) | 25 (dead) | 2 (dead) | 2 (alive) | 49 (dead) |